Concepedia

Kiran Klaus Patel

KK

Statistics

Publications

25

Citations

4K

H-Index

19

Active since

2004

Affiliations

Maastricht University(Current)

Incyte (United States)

GlaxoSmithKline (United States)

Palo Alto Institute

Massachusetts General Hospital

Kiran Klaus Patel is an author at Maastricht University specializing in oncology, social sciences, and medicine.

ORCID

Publications per year

2004–2022

25

Publications

25

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

, , +17

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 512 citations · Full text

, , +17

Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

Georgina V. Long, Jeffrey S. Weber, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2016 · 287 citations

, , +14

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Douglas B. Johnson, Keith T. Flaherty, Jeffrey S. Weber et al. · Journal of Clinical Oncology · 2014 · 212 citations · Full text

, , +14

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

J Cassidy, J.-Y. Douillard, C.J. Twelves et al. · British Journal of Cancer · 2006 · 125 citations · Full text

, , +17

1–5 of 25